Search Results for keywords:"biotechnology"

In Executive Order 14236, the President has decided to rescind additional executive orders and actions that were put in place during the prior administration. This order, building on a previous executive order from January 20, 2025, is aimed at restoring "common sense" and encouraging American potential. A number of executive orders, memoranda, and presidential determinations, primarily focused on areas like COVID-19 response, energy supply, worker empowerment, and biotechnology, have been revoked. The order clarifies that it does not change any legal authority, is subject to applicable laws, and does not create legal rights for any party.

The National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), is considering giving Ziopharm Oncology, Inc. an exclusive patent license to develop and market certain cancer therapies. These therapies involve using a patient's own T cells that are engineered to target specific mutations in the P53 gene, which is commonly mutated in many cancers. The license will cover treatments made through a method known as transposon-mediated gene transfer but will not include those made using CRISPR technology. Interested parties have until February 9, 2021, to submit comments or license applications.

The Environmental Protection Agency (EPA) issued a final rule that provides an exemption from the requirement of a tolerance for residues of the Bacillus thuringiensis Cry1B.34 protein in corn. This means that the Cry1B.34 protein, used as a Plant-Incorporated Protectant (PIP) in various types of corn, does not require a specific maximum residue level. After evaluating the available safety data, the EPA concluded that the protein is safe and poses no significant risk to human health, including for infants and children. This exemption eliminates the need for numerical limits on Cry1B.34 protein residues, allowing its use without the traditional tolerance requirement.

The National Science Foundation (NSF) announced a virtual meeting of the Advisory Committee for Mathematical and Physical Sciences scheduled for March 10 and 12, 2021. This open meeting aims to provide advice on major goals and policies related to NSF's Mathematical and Physical Sciences programs. The agenda includes discussions on the state of these sciences, impacts of COVID-19, and future industries like biotechnology and advanced manufacturing. The meeting minutes and materials will be available on the NSF website or from a contact person at the foundation.

The U.S. Government owns a new invention for an improved live-attenuated vaccine targeting Respiratory Syncytial Virus (RSV) and is now offering it for licensing. The technology involves a vaccine developed by altering certain RSV genes to create a version of the virus that stays stable and is weakened enough to be safe for use as a vaccine. This vaccine could potentially help protect infants, young children, and older adults from serious respiratory diseases caused by RSV and is designed to be administered intranasally. The National Institute of Allergy and Infectious Diseases is looking for commercial partners to develop and evaluate this vaccine further.

The U.S.-China Economic and Security Review Commission is holding a public hearing on February 6, 2025, in Washington, DC. The hearing will discuss China's progress on its "Made in China 2025" goals, focusing on technology areas like biotechnology, aerospace, and robotics. This event will evaluate how China is handling industrial policies and the implications for the U.S. and its allies. The public can attend in person or view a live webcast, with no reservations needed.